Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer

By J. Fridman, E. Caulder, M. Hansbury, Xiangdong Liu, Genjie Yang, Qian Wang, Y. Lo, Bin-Bing S. Zhou, Max Pan, S. Thomas and 7 more. 2007

145 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

A Disintegrin and Metalloproteinase (ADAM) and ADAM with Thrombospondin Motifs (ADAMTS) Family in Vascular Biology and Disease (2019, background): “For instance, small molecule inhibitor INCB3619 have a potent inhibitory effect on ADAM-10 and ADAM-17, with less potent effect on ADAM-8, 9, and 33 [51].”
Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. (2009, background): “Notably, unlike the first generation MMPIs, INCB7839 did not induce musculoskeletal adverse effects in initial animal studies.(136)”
The ADAM metalloproteinases (2008, background): “In this regard, INCB3619 is a potent inhibitor of both ADAM-10 and -17 which reduced the processing of multiple EGFR ligands in vitro and in vivo in tumour-bearing mice, and reduced tumour growth appreciably (Fridman et al., 2007).”
A Disintegrin and Metalloprotease (ADAM): Historical Overview of Their Functions (2016, background): “An example is the INCB3619 which inhibits ADAM-8, -9, -10, -17, and -33, but with lower IC50 for ADAM-10 and -17 [79].”